HNF4A and hepatocellular carcinoma: Tsai et al. used MSNs to co-deliver conventional chemotherapeutic drug cisplatin and the master regulator of liver-specific gene expression, HNF4α, to simultaneously undergo chemotherapy and gene therapy in hepatocellular carcinoma.